Regulated Information - Global

Period

Filter by

Reset

Showing: 1 – 05 of 171 Regulated Information

Show

Sort

Ipsen presents strong full-year 2021 results and enters into exclusive negotiations to divest its Consumer Healthcare business

11 February 2022

11 February 2022

Download Ipsen presents strong full-year 2021 results and enters into exclusive negotiations to divest its Consumer Healthcare business

Ipsen presents strong full-year 2021 results and enters into exclusive negotiations to divest its Consumer Healthcare business

Attachment

FY 2021 – Results presentation (0 bytes)

Webcast replay FY 2021

Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership

17 December 2021

17 December 2021

Download Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership

Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership

Ipsen delivers strong sales growth for the first nine months and improves its full-year guidance

21 October 2021

21 October 2021

Download Ipsen delivers strong sales growth for the first nine months and improves its full-year guidance

Ipsen delivers strong sales growth for the first nine months and improves its full-year guidance

YTD 2021 – Sales presentation (0 bytes)

Share buyback program – Ipsen reporting from 19 to 23 July 2021 – Detailed

11 October 2021

11 October 2021

Share buyback program – Ipsen reporting from 19 to 23 July 2021 – Detailed

This article or press release has no online content. Please download the associated documents for more information.

Ipsen delivers strong H1 2021 results and upgrades full-year guidance

26 July 2021

26 July 2021

Download Ipsen delivers strong H1 2021 results and upgrades full-year guidance

Ipsen delivers strong H1 2021 results and upgrades full-year guidance

H1 2021 – Results presentation (0 bytes)

Webcast replay H1

1 … 29 30 31 32 33 34 35

This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.